Pace Locator
Pace Locator's aim is to leverage the potential of common, noninvasive patient data to enable faster, more reliable diagnosis and, eventually, safer, more successful treatment.
Pace Locator's aim is to leverage the potential of common, noninvasive patient data to enable faster, more reliable diagnosis and, eventually, safer, more successful treatment.
Pace Locator has raised $170k across 1 round. Its most recent round was a Series Unknown of $170k in Feb 2024. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Pace Locator is featured in
Similar companies
Multiwave develops breakthrough Magnetic Resonance Imaging and Positron Emission Tomography devices. Founded in Switzerland in March 2015, Multiwave Technologies AG has its headquarters in Geneva, Switzerland and a R&D facility in France.
Oryl Photonics develops a laboratory instrument for pharmaceutical and biotech companies that provides simple, reliable, cost-effective and sustainable solubility measurement to accelerate drug development for better and effective medicine.
Lumendo is a medtech startup that develops light-active medical fillers for elegant and time saving surgeries. The fillers allow time-saving surgery for the best patient outcome. These can be used to form implants in any cavity inside the body. Lumendo was founded on 2018 and is headquartered in Renens, Switzerland.
Positrigo is a company focused on creating, manufacturing, and marketing specialized PET scanners for the brain.
Liquid biopsies offer improved treatment options for a larger number of patients. Hedera Dx is committed to expanding access to advanced cancer treatment for the next billion people. We focus on developing NGS-based liquid biopsies that can be easily implemented in clinics, allowing for non-invasive diagnosis, timely treatment decisions, and ongoing disease tracking. Our company values include innovative thinking, modern approaches, and a human-centric culture, creating a dynamic and creative work atmosphere. Visit hederadx.com to find out more about joining our team.
Axmed is a company that specializes in serving low and middle-income countries (LMICs), with the goal of enhancing their ability to purchase affordable, high-quality medicines. We collaborate only with reputable pharmaceutical companies and certified healthcare providers to expedite the availability of medications.
EarlySight was created to expedite the advancement of technology and make it accessible in clinics.
Scanvio provides gynecologists with AI-enhanced ultrasound software to accelerate the diagnosis of endometriosis, enhancing their sonography skills and advancing medical and surgical education.
EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware and software components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Resmonics, established in October 2020 as a result of collaboration between ETH Zürich and University St. Gallen, specializes in developing a privacy-minded acoustic AI technology. This technology is designed to analyze the sound environment of a room, with a particular emphasis on identifying signs of infectious lung diseases. Through its product line, Quorum, Resmonics integrates this AI with air quality sensors and noise analysis tools to create conducive and efficient working environments.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.